# Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

> **NCT03987815** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03987815
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03987815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03987815, "Neoadjuvant Nivolumab for Operable Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03987815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*